# The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis

> **NCT02632786** · PHASE2 · COMPLETED · sponsor: **Prothena Biosciences Ltd.** · enrollment: 129 (actual)

## Conditions studied

- AL Amyloidosis

## Interventions

- **DRUG:** NEOD001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02632786
- **Lead sponsor:** Prothena Biosciences Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2018-03
- **Final completion:** 2018-03
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2019-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02632786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02632786, "The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02632786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*